

## STALLERGENES GREER SHAREHOLDERS APPROVE ALL RESOLUTIONS PROPOSED BY THE BOARD OF DIRECTORS AT THE ANNUAL GENERAL MEETING

**London (UK), June 7, 2018** – The shareholders of Stallergenes Greer plc, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that all resolutions proposed by the Board of Directors at the company's Annual General Meeting (AGM) were duly passed today. All resolutions were set out in the Notice of Meeting posted to shareholders on 23 April 2017.

Notably, shareholders re-elected Chairman and CEO Fereydoun Firouz, and Directors, Jean-Luc Bélingard, Rodolfo Bogni, Stefan Meister, Yvonne Schlaepfi and Elmar Schnee – each for a further term of one year.

The terms of Patrick Langlois and Paolo Ricci have expired at the end of the AGM. The Board would like to thank both Patrick for his contributions to Stallergenes Greer as a Board member and Chair of the Audit Committee, and Paola for her contributions as a Board member.

In addition, Philip Broadley was elected as a Director with a one-year term. Mr Broadley has significant financial and international business experience, having previously been Group Finance Director of Prudential plc for eight years and Old Mutual plc for six years. He is currently a director of AstraZeneca plc and serves on their Audit Committee, and is also a director and the Audit Committee chairman of Legal & General Group plc. He is a member of the Oxford University Audit Committee, Treasurer of the London Library and Chairman of Governors at Eastbourne College. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Mr Broadley started his career at Arthur Andersen where he was a partner for seven years. He is a past Chairman of the 100 Group of Finance Directors in the UK and served as a member of the Code Committee of the Takeover Panel. He graduated in Philosophy, Politics and Economics from St Edmund Hall, Oxford and has an MSc in Behavioural Science from the London School of Economics.

“2017 continued a transformation at Stallergenes Greer to improve our operations, serve our customers and deliver a strong performance. I would like to thank all of our Directors for their contributions and guidance, and our shareholders for their continued support. I would also like to welcome Philip Broadley to our Board of Directors. Philip has extensive experience in corporate finance and will be a valuable contribution to our Board and Audit Committee where he will serve as Chair,” said Chairman and CEO, Fereydoun Firouz, “We remain focused and committed to strengthening our leadership position, driving excellence across our business and positioning our company for long-term growth in order to deliver value to our shareholders, customers and employees.”

The full text of each resolution is set out in the Notice of Annual General Meeting, which is available on Stallergenes Greer's website at [www.stallergenesgreer.com](http://www.stallergenesgreer.com).

### ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the US) and Stallergenes SAS (whose registered office is in France).

### TRADING INFORMATION

Name: Stallergenes Greer  
ISIN: GB00BZ21RF93 1 - Ticker: STAGR  
ICB Classification: 4577  
LEI: 213800CYVZA7GJQEME86  
Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>.

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2016 annual report published on 16 April 2018 on the Company's website [www.stallergenesgreer.com](http://www.stallergenesgreer.com). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

<b>CONTACTS</b>	
<b>Communications and Investor Relations</b> Natacha Gassenbach Tel: +1 (617) 682 2626 Email: <a href="mailto:natacha.gassenbach@stallergenesgreer.com">natacha.gassenbach@stallergenesgreer.com</a>	<b>Media Relations Agency</b> Havas Paris (Europe) Samuel Rousseau +33 6 77 88 32 43 E-mail : <a href="mailto:samuel.rousseau@havas.com">samuel.rousseau@havas.com</a>
Caitlin Stefanik Tel: +1 (857) 331 4117 Email: <a href="mailto:caitlin.stefanik@stallergenesgreer.com">caitlin.stefanik@stallergenesgreer.com</a>	<b>Investor Relations Agency</b> FTI Consulting Arnaud de Cheffontaines Tel: +33 1 47 03 68 10 Email: <a href="mailto:stalleregenesgreer@fticonsulting.com">stalleregenesgreer@fticonsulting.com</a>